In contrast, histone deacetylase inhibitor valproic acid (VPA) pre-treatment significant increased the surface expression of FLT3-ITD, phosphorylated ERK and phosphorylated AKT were then increased, and the susceptibility of AML cells to rapamycin was enhanced [22]. Here, FLT3 is linked to acute myeloid leukemia.